drugset
drugset / Trial / NCT02167594

Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers

NCT02167594 ↗

Phase 1 Completed 29 enrolled Avid Radiopharmaceuticals
Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.

Timeline

Start
2014-08-12
Primary completion
2016-07-11
Completion
2016-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Flortaucipir Diagnostic / imaging agent 370 mbq Intravenous

Indications

corticobasal degeneration disorder progressive supranuclear palsy